The very favorable safety and tolerability profile of AEF0117 enables the Phase 2b study to be confidently continued, with first results expected in mid-2024. $AELIS #AELIS #biotech #cannabisaddiction #innovation #clinicaltrials

🙋 L'HMar Research Institute ha posat en marxa un #assaigclínic per a la millora de les #funcionscognitives en persones amb la síndrome de #Down En voleu saber més coses? Aquí la trobareu 👉 bit.ly/3VBLTRM #ICODProject ICOD_Project Aelis Farma Down Catalunya

🙋 L'HMar Research Institute ha posat en marxa un #assaigclínic per a la millora de les #funcionscognitives en persones amb la síndrome de #Down En voleu saber més coses? Aquí la trobareu 👉 bit.ly/3VBLTRM #ICODProject ICOD_Project Aelis Farma Down Catalunya

🙋 L'HMar Research Institute ha posat en marxa un #assaigclínic per a la millora de les #funcionscognitives en persones amb la síndrome de #Down En voleu saber més coses? Aquí la trobareu 👉 bit.ly/3VBLTRM #ICODProject ICOD_Project Aelis Farma Down Catalunya

We are proud to announce that Pier Vincenzo Piazza, CEO of Aelis Farma, receives the Distinguished Achievement Award from the Eur Behav Pharm Soc. for his contribution to the advancement of research in the field of neuroscience 👏 $AELIS #cannabisaddiction #neuroscience #braindiseases

🙋 L'HMar Research Institute ha posat en marxa un #assaigclínic per a la millora de les #funcionscognitives en persones amb la síndrome de #Down En voleu saber més coses? Aquí trobareu més informació 👉 bit.ly/3VBLTRM #ICODProject ICOD_Project Aelis Farma Down Catalunya

Hem posat en marxa un #assaigclínic per a la millora de les #funcionscognitives en persones amb la síndrome de #Down Si necessiteu més informació de l'#ICODProject 👇👇👇 bit.ly/3VBLTRM Hospital del Mar ICOD_Project Aelis Farma Down Catalunya

Discover the half-year financial results and update on the development for 2023 of Aelis Farma 👇 $AELIS #AELIS #biotech #downsyndrome #cannabisaddiction #halfyearresults

🥼​​ #Sanidad | El nuevo enfoque actúa sobre el receptor cannabinoide CB1, optimizando la actividad cerebral y reduciendo el esfuerzo para tareas de memoria Aelis Farma Down Catalunya s.mtrbio.com/kulpkpmsra

The Aelis Farma team wishes you a promising and successful 2025! 🌟 2024 was a landmark year for us, with major strides in the clinical development of our CB1-SSi drug candidates, AEF0117 and AEF0217. 2025 promises to be a year of growth, innovation and impact. 🌍

🧠This Brain Awareness Week, let's celebrate neuroscience advancements ! Understanding the brain is key to treating neurological disorders. At Aelis Farma, we pushes the boundaries of innovation to develop breakthrough therapies.

🚀 Aelis Farma at the heart of healthcare innovation We are proud to announce that Stéphanie Monlezun, COO of Aelis Farma, will be participating in the conference organized by Big Media – Bpifrance. #Innovation #Health #Biotech #BigMedia #Bpifrance #AelisFarma

🛡️ Patient Safety Week 2025: Safety by Design at Aelis Farma Patient safety isn’t a box to tick — it’s how we design our medicines from day one. #PatientSafetyWeek #DrugSafety #CB1 #AelisFarma #DownSyndrome #CannabisUseDisorder

📢 Aelis Farma announces its H1 2025 financial results and key development milestones Read the full press release here 👉 s3.eu-central-1.amazonaws.com/aelis.investor… #HalfYearResults #AelisFarma #CB1 #CB1SSi #Downsyndrome #CannabisAddiction #CUD #Obesity $AELIS

At BIG Media 2025, Stéphanie Monlezun spoke at the round table discussion “Medicine of tomorrow: what innovations for the future of health?” alongside Stan Larroque (Lynx Mixed Reality), Noé Poyet (GLEAMER), and Pierrick Tiret (Caisse d'Epargne Hauts de France). 📸 Some pictures

➡️ 1 in 8 people worldwide live with a neuropsychiatric disorder. At Aelis Farma, we are developing a new pharmacological class, Signaling Specific inhibitors of the CB1 receptor (CB1-SSi), which modulate the activity of this receptor involved in numerous brain disorders.

🔬 On this National Drug Abuse Prevention Day, we reaffirm our commitment to delivering a safe therapeutic solution for cannabis use disorders and to advancing AEF0117 with partners.

Dr Pier Vincenzo PIAZZA was interviewed by L’Esprit Curieux 🎙️ Watch the full interview here: youtube.com/watch?v=1S-7Kk…

🧬 Aelis Farma at BIO-Europe 2025 in Vienna! Discover Aelis Farma's projects at this major European biotechnology and pharmaceutical industry event—represented on site by our partner Staatz Business Development & Strategy.

🌍 On World Diabetes Day, Aelis Farma reaffirms its commitment to advancing CB1 biology and CB1-SSi therapies to better understand and treat diseases in which CB1 plays a central role, including metabolic diseases such as type 2 diabetes.